| GTO ID | GTC2682 |
| Trial ID |
NCT04880434
|
| Disease |
Mantle Cell Lymphoma
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KTE-X19|Tecartus|Brexucabtagene autoleucel |
| Location approved | US, EU, UK, Australia, Canada |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) |
| Year | 2021 |
| Country | France|Germany|Netherlands|Spain|United Kingdom|United States |
| Company sponsor | Kite, A Gilead Company |
| Other ID(s) | KTE-C19-102 (Cohort 3)|2015-005008-27 |